Every 10-Q that Hoth Therapeutics, Inc. (HOTH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow HOTH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HOTH filings page.
Hoth Therapeutics reported a quarterly net loss of approximately $2.7 million, improving from about $3.5 million a year earlier, with no product revenue. Research and development expenses were roughly $1.5 million and general and administrative costs about $1.1 million, both down year over year.
Cash and cash equivalents were $4.0 million as of March 31 2026 against an accumulated deficit of roughly $75.6 million, and management states that these conditions raise substantial doubt about the company’s ability to continue as a going concern without additional capital. During the quarter Hoth raised about $0.7 million via its at‑the‑market program and subsequently closed a separate equity and warrant financing with gross proceeds of about $2.0 million to help fund ongoing clinical programs.
Hoth Therapeutics (HOTH) filed its Q3 2025 10‑Q, reporting no revenue and a net loss of $4.11 million for the quarter as operating expenses reached $4.08 million. For the nine months, the company recorded a net loss of $9.78 million.
Liquidity remained stable with cash and cash equivalents of $7.85 million as of September 30, 2025. Year‑to‑date, the company used $7.65 million in operating cash and received $8.76 million from financing, including warrant exercises and equity sales. Management states current cash is sufficient to fund operations for at least 12 months from the issuance date of these financial statements, while noting additional capital will be needed to advance programs.
The company maintained an ATM program with total capacity of $7.7 million; approximately $5.5 million of common stock had been sold under the program as of November 11, 2025. Shares outstanding were 15,514,312 as of November 11, 2025. Hoth also reported crypto assets at fair value of $274,695 (BTC, ETH, SOL). Equity activity included the CEO’s 800,000-share restricted stock grant in August.
Hoth Therapeutics, Inc. reported $9.0 million in cash and cash equivalents at June 30, 2025, up from $7.0 million at year-end 2024, and total assets of $10.1 million. The company recorded a six-month net loss of $5.68 million versus $3.86 million in the prior-year period, driven in part by a $1.25 million immediate expensing of acquired patent applications and higher research and development spending. Weighted average shares increased materially, lowering six-month loss per share to $0.44 from $0.68 a year earlier despite a larger absolute loss.
Operating cash used was $5.16 million for the six months, while financing activities provided $7.13 million, including $5.625 million from warrant exercises. Management states current cash is sufficient to fund operations for at least 12 months from issuance, but additional capital will be required for longer-term development and regulatory plans. The company continues clinical and preclinical programs across multiple candidates and maintains an ATM facility with selling capacity expanded to $7.7 million.